Unique ID issued by UMIN | UMIN000008124 |
---|---|
Receipt number | R000009565 |
Scientific Title | Phase II study of Pemetrexed and Bevacizumab in Performance status 2 patients with advanced non-squamous non-small cell lung cancer. |
Date of disclosure of the study information | 2012/06/08 |
Last modified on | 2018/06/14 10:42:37 |
Phase II study of Pemetrexed and Bevacizumab in Performance status 2 patients
with advanced non-squamous non-small cell lung cancer.
Phase II study of Pemetrexed and Bevacizumab in PS2 patients with advanced non-squamous non-small cell lung cancer.
Phase II study of Pemetrexed and Bevacizumab in Performance status 2 patients
with advanced non-squamous non-small cell lung cancer.
Phase II study of Pemetrexed and Bevacizumab in PS2 patients with advanced non-squamous non-small cell lung cancer.
Japan |
non-squamous non-small cell lung cancer
Medicine in general | Hematology and clinical oncology |
Malignancy
NO
To evaluate the response rate and feasibility of Pemetrexed and Bevacizumab in Performance status 2 patients with advanced non-squamous non-small cell lung cancer.
Safety,Efficacy
Exploratory
Pragmatic
Phase II
PFS
RR,DCR,OS,TTF,QOL,safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Pemetrexed and Bevacizumab administered every 3 week until observation of progression or intolerable toxicity.
20 | years-old | <= |
Not applicable |
Male and Female
1) StageIIIB/IV or postoperative recurrence Non-small cell lung cancer and Non-Squamous cell carcinoma proven by histology and/or cytology
2) EGFR mutation or ALK rearrangement status is not required
3) No prior chemotherapy
4) 20 years or older and PS 2
5) At least one or more measurable lesion by RECIST ver1.1
6) Adequate organ function
7) Interval
-Palliative radiotherapy >4wks
-Surgery >4wks
-thoracic drainage>1wks
-biopsy with dissection, indwelling port >1wks
-blood transfusion >2wks
8) Life expectancy more than three months.
9) Written Informed Consent
1) History of hemoptysis
2) High risk of bleeding or thrombus events
3) History of anticoagulant within 10 days before enrollment
4) Active radiation pneumonitis or esophagitis
5) Uncontrollable hypertension
6) Symptomatic brain metastasis
7) Scheduled operation
8) Severe complications
9) Problematic infection
10) History of active double cancer
11) No intention to birth control
12) Unstable psychic disorder
13) History of treatment drug
14) Decision of ineligibility by a physician.
25
1st name | |
Middle name | |
Last name | Hirohisa Yoshizawa |
Niigata University Medical and Dental Hospital
Bioscience Medical Research Center
1-754 Asahimachi-Dori,Niigata City, Niigata 951-8520
025-227-2517
hy0522@med.niigata-u.ac.jp
1st name | |
Middle name | |
Last name | Hirohisa Yoshizawa |
Niigata University Medical and Dental Hospital
Bioscience Medical Research Center
1-754 Asahimachi-Dori,Niigata City, Niigata 951-8520
025-227-2517
hy0522@med.niigata-u.ac.jp
Niigata Lung Cancer Treatment Group
Niigata Foundation for the Promotion of Medicine
Non profit foundation
Japan
NO
燕労災病院(新潟県)
厚生連長岡中央綜合病院(新潟県)
国立病院機構西新潟中央病院(新潟県)
済生会新潟第二病院(新潟県)
上越総合病院(新潟県)
新潟県立がんセンター(新潟県)
新潟県立吉田病院(新潟県)
新潟県立新発田病院(新潟県)
新潟県立中央病院(新潟県)
新潟市民病院(新潟県)
新潟大学医歯学総合病院(新潟県)
新潟労災病院(新潟県)
長岡赤十字病院(新潟県)
2012 | Year | 06 | Month | 08 | Day |
Unpublished
Open public recruiting
2012 | Year | 03 | Month | 02 | Day |
2012 | Year | 06 | Month | 01 | Day |
2015 | Year | 06 | Month | 01 | Day |
2016 | Year | 06 | Month | 01 | Day |
2016 | Year | 10 | Month | 01 | Day |
2016 | Year | 12 | Month | 01 | Day |
2012 | Year | 06 | Month | 08 | Day |
2018 | Year | 06 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009565